Investors might want to bet on Brainsway Ltd. Sponsored ADR (BWAY) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earni ...

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $6.82, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11.75 indicates a 72.3% upside potential. The average comprises four short-term price targets ranging from a low of $9 to a high of $15, with a standard deviation of $2.50. While the lowest estimate indicates an increase of 32% from the curren ...

财务数据和关键指标变化 - 第二季度收入为1000万美元,同比增长28% [7][15] - 毛利率为75%,较上年同期的73%有所提升 [15] - 第二季度实现净利润60万美元,上年同期为净亏损170万美元 [18] - 连续第四个季度实现正的经调整EBITDA和经营活动现金流 [17] - 截至6月30日,现金和短期存款余额为48.1亿美元,无债务 [19] 各条业务线数据和关键指标变化 - 前两个季度共出货114台Deep TMS系统,同比增长13%,累计安装量达1215台 [9] - OCD治疗适应症需求保持强劲,约50%的安装基础具备OCD治疗能力 [10] - 继续加强和拓展与大型机构和企业客户的合作伙伴关系 [10] 各个市场数据和关键指标变化 - 国际市场占比约20%,亚太地区尤其是印度、韩国、台湾、泰国需求强劲,欧洲如法国、意大利、西班牙也有很大需求 [22] - 6月宣布与加拿大一家大型专业分销商签署独家多年分销协议,首年订单11台Deep TMS系统,后续年度逐步增加 [11] 公司战略和发展方向及行业竞争 - 继续推进360系统在多个适应症的试点项目,相信这将成为未来主要技术之一 [24] - 正在与多家合作伙伴就成瘾症适应症的分销渠道进行洽谈 [24] - 通过自身渠道拓展和新适应症获批等方式,持续加大销售和营销投入以加速增长 [25][26] 管理层对经营环境和未来前景的评论 - 对下半年及全年业绩保持乐观,预计2024年全年收入将增长21%-25%至38.5-40亿美元 [8][19] - 盈利能力和现金流正面趋势将延续全年 [8][38] - 看好国内外市场需求持续增长,将继续加大投资以加快渠道拓展和新适应症开发 [26][44] 其他重要信息 - FDA批准Deep TMS系统适应症扩大至22-86岁MDD患者,这是TMS领域首次获得此类批准 [12] - 正在开展加速MDD治疗方案的临床试验,有望提高患者便利性 [13] 问答环节重要的提问和回答 问题1 **Steve Lichtman 提问** 国际市场占比及未来重点区域 [21] **Hadar Levy 回答** 国内外占比约80%/20%,亚太地区如印度、韩国、台湾、泰国需求强劲,欧洲如法国、意大利、西班牙也有很大需求 [22] 问题2 **Jeffery S. Cohen 提问** 加速MDD治疗方案的具体情况 [27][28] **Hadar Levy 回答** 从30天缩短至6天,每天多次治疗 [28] 问题3 **Unidentified Analyst 提问** 未来盈利能力及增长动力 [37][38][39][40] **Hadar Levy 回答** 计划保持盈利,通过大型企业客户拓展、OCD适应症需求增加、灵活的商业模式等推动持续增长 [38][39][40]

Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Fourth Consecutive Quarter Raising Lower End of Full-Year 2024 Revenue Guidance to Range of $38.5 Million to $40 Million Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global lead ...

Brainsway Ltd. Sponsored ADR (BWAY) shares rallied 9.3% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.6% gain over the past four weeks. Shares of Brainsway has been rising for the past three months on the back of its solid first-quarter performance. The recent price rise is likely due to positive sentiments of investors that is likely to continue as the compa ...

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the re ...

BrainsWay Ltd. (BWAY) recently signed an exclusive multi-year distribution agreement with a specialty distributor serving both the acute hospital and non-acute healthcare spaces in Canada. The deal will enable the company to make a broad market entry into Canada for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) system. Per management, a significant mental health crisis is prevalent in Canada, with the current existence of a substantial barrier to treatment. One in two Canadians have, or ...

Deep TMS is delivered through a patented coil design which is housed within a cushioned, patient and providerfriendly helmet. By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system can stimulate important neural networks involved in mental health conditions. BrainsWay's unique therapeutic solution is currently cleared in Canada to treat major depressive disorder and obsessive-compulsive disorder. BrainsWay is a global leader in advanced noninvasive neurostimulation tr ...

文章核心观点 - 公司启动了一项临床试验,旨在评估其Deep TMS系统在治疗主要抑郁障碍(MDD)方面的新型加速治疗方案的疗效 [1][3] - 这项临床试验是公司致力于通过创新研究和优秀科学来推进心理健康治疗的一个重要步骤 [2] - 该加速治疗方案可能会提高Deep TMS的患者便利性,从而增加其在心理健康市场的应用和公司的价值主张 [5][6] 根据相关目录分别进行总结 临床试验详情 - 该临床试验将招募100多名MDD患者,分为两组,一组接受新型加速治疗方案,另一组接受FDA批准的标准治疗方案 [3] - 这项非劣效性试验旨在比较加速方案与标准方案的疗效 [3] - 该试验目前正在美国多个地点进行招募 [4] 试验的潜在价值 - 公司表示,加速方案可能会产生与传统较长方案相当的疗效,并能显著提高患者的便利性 [5] - 加速治疗方案可能会提高Deep TMS的患者接受度,从而增强公司在心理健康市场的价值主张 [6] 行业前景 - 根据Market.us报告,全球经颅磁刺激仪市场规模预计将从2023年的12亿美元增长到2033年的30亿美元,复合年增长率为9.3% [7] 公司股价表现 - 过去一年,公司股价上涨191.5%,而行业仅增长0.8% [8]

About BrainsWay Investors: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com The clinical trial is anticipated to enroll over 100 patients with major depressive disorder (MDD) who will be split into two groups – one receiving a novel accelerated treatment protocol featuring an acute phase over several treatment days, and the other receiving the FDA-cleared standard-of-care protocol which entails an acute phase over several weeks. The design of this non-inferiority trial, which was determined in di ...